Centessa Pharmaceuticals plc
CNTA
$11.57
$0.302.66%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.63% | 11.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.72% | 5.51% | |||
| Operating Income | -60.72% | -5.51% | |||
| Income Before Tax | -162.83% | 2.67% | |||
| Income Tax Expenses | 72.70% | -13.76% | |||
| Earnings from Continuing Operations | -161.54% | 2.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -161.54% | 2.85% | |||
| EBIT | -60.72% | -5.51% | |||
| EBITDA | -60.81% | -5.53% | |||
| EPS Basic | -130.29% | 8.52% | |||
| Normalized Basic EPS | -56.85% | 7.22% | |||
| EPS Diluted | -130.29% | 8.52% | |||
| Normalized Diluted EPS | -56.85% | 7.22% | |||
| Average Basic Shares Outstanding | 13.59% | 6.18% | |||
| Average Diluted Shares Outstanding | 13.59% | 6.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
